Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 112

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 112
---
 these indications can facilitate expedited regulatory endorsements, such as orphan drug status or breakthrough therapy designation, enhancing ARB’s attractiveness to potential partners and acquirers. |

| ● | Strategic Regulatory Engagement: Pursue early and continuous engagement with regulatory bodies to navigate the development process efficiently, utilizing programs like the FDA’s Fast Track and Priority Review to shorten the timeline to market authorization. |

| ● | Robust IP Portfolio Development: Aggressively expand and protect the intellectual property landscape around ARB, including its unique liposomal formulation manufacturing methods and potential use cases across various solid tumors. |

| ● | Data Publication and Presentation: Strategically release clinical trial results and other key data milestones at major oncology conferences and in high-impact journals to maximize visibility and interest from the oncology community, investors, and potential acquirers. |

| ● | Timely Exit Considerations: Evaluate exit opportunities following pivotal Phase 2 efficacy data, which often serves as an inflection point in valuation for emerging oncology therapies, balancing the potential for further value appreciation against the risks and costs of later-stage development. |

| ● | Expanding                                                                                                                                    
 Therapeutic Range: Broaden the scope of ARB’s development program to explore its potential across a diverse array of solid                   
 tumors, capitalizing on the versatility of the liposomal formulation to address multiple facets of the TME. This expansion can significantly 
 enhance ARB’s market potential and long-term value.                                                                                          |

| ● | Enduring                                                                                      
 Partnerships and Collaborations: Forge and maintain strategic partnerships with academic      
 institutions, research organizations, and cancer advocacy groups to advance ARB’s development 
 and adoption. Engaging with the broader oncology community can foster support for ARB’s       
 innovative approach to cancer treatment. We also plan to engage with major pharmaceutical     
 companies regarding existing cancer therapy products in the market, aiming to collaborate     
 and integrate our combination therapy nano-ARB with approved treatments. This collaboration   
 aims to facilitate lower doses, improve toxicity profiles, enhance treatment efficacy, and    
 reduce resistance to current therapies.                                                       |

By adhering to this multi-path strategy,
the Company is planning to ensure that the ARB project is optimally positioned to navigate the complexities of the oncology field, from
developmental hurdles to regulatory approvals and market entry, aligning our efforts with the ultimate goal of transforming cancer treatment
paradigms.

In this regard, we note
that there can be no assurance that we will be able to secure above referenced development partnerships or collaborations. However, we